Dr. David Hay is the Chair of Tissue Engineering at the University of Edinburgh, where his group is defining novel ways to produce liver tissue from PSCs. They use in vitro derived tissue to better model human liver physiology and to develop supportive cell based therapies for disease. Dr. Hay also founded Stimuliver, a company that is developing a disruptive liver implant to treat critically failing liver function in humans. He talks about hepatocyte differentiation, liver disease modeling, and automating the production of cell therapies.
In this special episode of the Stem Cell Podcast, we speak with three postdocs from different parts of the world about their research in and outside of the lab. Drs. Bria Macklin, Matthew Sinton, and Leili Rohani discuss their research on vascularization, immunometabolism, and cardiac tissue engineering, respectively, as well as their long-term career goals.